|Name||PRICE||MARKET CAPITALIZATION||PRICE TO EARNINGS RATIO||DIVIDEND YIELD||SYMBOL||EXCHANGE||PRICE PERCENT DIFFERENCE||YEAR TO DATE PRICE PERCENT DIFFERENCE||5 YEAR CHART||1 YEAR CHART|
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.
ALLK $36.30 -1.72 (-4.52%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 1.64 Billion
EPS 0.14 P/E Ratio 0.00
Previous Earnings Thu, Nov 8, 2018
Latest Earnings Thu, Mar 14, 2019
Dividend Pay Date --
Dividend History --
This list of trending stocks may change throughout the trading day.
Investing Quotes #Legendary
Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.
Some links on this website are advertisements and/or affiliate links and Symbol Surfing receives compensation.